4.5 Review

Commercially available assays for multiplex detection of alpha human papillomaviruses

期刊

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 8, 期 10, 页码 1139-1162

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/ERI.10.104

关键词

cervical cancer; diagnosis; HPV; human papillomaviruses; PCR

资金

  1. Abbott
  2. Digene
  3. Innogenetics
  4. Roche
  5. Seegene

向作者/读者索取更多资源

Five main groups of commercial assays for the multiplex detection of alpha human papillomaviruses (HPVs) are currently available. DNA-based screening assays, which test for the presence of 13-14 HPVs without determination of HPV type, have been the standard for HPV detection in the last decade. Assays that combine testing for 14 HPVs and HPV-16 and HPV-18 genotyping are a potential future standard for HPV detection. The clinical value of HPV genotyping assays has still not been finally determined. Recently, one of the mRNA-based assays showed equal clinical sensitivity but higher clinical specificity for CIN2+/CIN3+ in comparison with the validated DNA-based assay. In situ hybridization assays are too laborious and have insufficient clinical sensitivity to be used in routine screening. Automation, price reduction and improvement of clinical specificity are the main goals for the future development of HPV assays.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据